RHRikke Boedker Holmstroem

Rikke Boedker Holmstroem

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rikke Boedker Holmstroem has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prospective study of patients with immune checkpoint inhibitor-induced hepatitis; characterization of liver injury, outcome of therapy, and management of steroid-unresponsive and steroid-dependent hepatitis

    by Rikke Boedker Holmstroem, Ane Soegaard Teisner, Mark Wilhelmus Dirk Sweep, Inge Mansfield Noringriis, Shawez Khan, Niels Kristian Aagaard, Jacob Karlström, Rebecca Schou Jurlander, Joel E Sohlin, Tine Juul Monberg, et al.

    Background: Immune-related hepatitis (ir-hepatitis) ranks among the most frequent adverse events of immune checkpoint inhibitors (ICIs). Limited knowledge exists regarding the incidence, characteristics, and treatment of patients having an inadequate response to initial therapy with steroids. Characterizing ir-hepatitis phenotypes and treatment responses can provide valuable insights for guiding treatment decisions and prognosis. Methods: This is a prospective study including patients treated with ICIs experiencing grade 3–4 ir-hepatitis. All patients received methylprednisolone 2 mg/kg for at least 72 hours and underwent liver biopsy. Ursodeoxycholic acid was added in mixed and cholestatic drug-induced liver injury (DILI) phenotypes, and mycophenolate mofetil (MMF) was added in patients with inadequate response to steroids. Multiplex immunohistochemistry (mIHC) for CD3, CD8, FoxP3, CD20, and CD56/NKp46 was used on liver biopsies, and single-cell RNA sequencing of peripheral blood samples was employed to characterize the immunological response. Results: A total of 34 patients with ir-hepatitis were included, of which 20 patients (59%) responded to steroids. Six patients (18%) were steroid-unresponsive and needed MMF. Eight patients (23%) had steroid-dependent ir-hepatitis; they had an initial response to steroids but relapsed during tapering. Patients with steroid-unresponsive and steroid-dependent ir-hepatitis were treated with significantly higher accumulated steroid doses. Alcohol consumption and male sex were significantly related to inadequate response to steroids. Patients with mixed DILI had the highest steroid response rates (72%), while only half of the patients with hepatocellular and cholestatic DILI responded. Patients with cholestatic DILI had the worst prognosis concerning management of ir-hepatitis, risk of cancer progression and death. MIHC of liver biopsies revealed significantly increased T cell infiltration in ir-hepatitis, including cytotoxic, helper and regulatory T cells. Single-cell RNA sequencing of blood samples showed CD8+ effector T cell clonal expansion in a patient with steroid-unresponsive ir-hepatitis than in a steroid responder. Conclusion: Nearly half of patients developing ir-hepatitis had an inadequate response to steroids and needed MMF as a secondary immunosuppressant. Patients with mixed DILI were more likely to respond to steroids, while alcohol consumption was associated with inadequate steroid response. Immune analyses showed high T cell infiltration in the liver among patients with ir-hepatitis. Trial registration number: ClinicalTrials.gov ID number NCT04810156 and EudraCT no. 2020-004483-26.


  • Open Access

    Safety and feasibility of blood-derived multiple antigen-specific endogenously derived T cells (MASE-T) for metastatic melanoma

    by T.J. Monberg, S.A. Tvingsholm, M. Svensson-Frej, C. Vestergaard, M. Ormhøj, J.W. Kjeldsen, T.H. Borch, R.B. Holmstroem, N. Jayashankar, J.S. Granhøj, et al.

  • Open Access

    Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report

    by Rikke Boedker Holmstroem, Emilie Kristine Dahl, Morten Helms, Henrik Vedel Nielsen, Janne Bayer Andersen, Jacob Tveiten Bjerrum, Inge Marie Svane, Eva Ellebaek, Jakob Benedict Seidelin

    Background Immune checkpoint inhibitors (ICIs) can induce a wide range of immune-related adverse events (irAEs), potentially affecting any organ. ICI-induced colitis is a frequently reported irAE, whereas enteritis is rare and not well documented. Case presentation We are presenting a patient with metastatic melanoma who developed severe ICI-induced enterocolitis multirefractory for glucocorticoids, infliximab and vedolizumab, partially responding to faecal microbiota transplantation and final complete response to tofacitinib. Conclusion This case supports that tofacitinib may be an(other) effective agent in managing multirefractory ICI-induced diarrhoea caused by colitis and/or enteritis.


  • Open Access

    COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis

    by Rikke Boedker Holmstroem, Ole Haagen Nielsen, Søren Jacobsen, Lene Buhl Riis, Susann Theile, Jacob Tveiten Bjerrum, Peter Vilmann, Julia Sidenius Johansen, Mogens Karsbøl Boisen, Rikke Helene Løvendahl Eefsen, et al.

    Background Immune-related adverse events due to immune checkpoint inhibitors (ICIs) are not always effectively treated using glucocorticoids and it may negatively affect the antitumor efficacy of ICIs. Interventional studies of alternatives to glucocorticoids are lacking. We examined whether interleukin-6 blockade by tocilizumab reduced ICI-induced colitis and arthritis. Patients and methods Patients with solid cancer experiencing Common Terminology Criteria for Adverse Events (CTCAE v5.0) grade >1 ICI-induced colitis/diarrhea (n=9), arthritis (n=9), or both (n=2) were recruited and treated with tocilizumab (8 mg/kg) every 4 weeks until worsening or unacceptable toxicity. Patients were not allowed to receive systemic glucocorticoids and other immunosuppressive drugs within the 14-day screening period. The primary endpoint was clinical improvement of colitis and arthritis, defined as ≥1 grade CTCAE reduction within 8 weeks. Secondary endpoints were improvements and glucocorticoid-free remission at week 24; safety; radiologic, endoscopic, and histological changes; and changes in plasma concentrations of C reactive protein, cytokines (IL-6, IL-8, and IL-17), and YKL-40. Results Nineteen patients were available for efficacy analysis; one patient was excluded due to pancreatic insufficiency-induced diarrhea. Patients received treatment with pembrolizumab (n=10) or nivolumab (n=4) as monotherapy or ipilimumab and nivolumab (n=5) combined. Seven patients had been initially treated with glucocorticoids, and two of them also received infliximab. Ten patients continued ICI therapy during tocilizumab treatment. The primary endpoint was achieved in 15 of 19 (79%) patients. Additional one patient had ≥1 grade reduction at week 10, and another patient had stabilized symptoms. At week 24, ongoing improvement without glucocorticoids (n=12), including complete remission (n=10), was noted. Five patients had grades 3–4 treatment-related adverse events, which were manageable and reversible. Conclusions Tocilizumab showed promising clinical efficacy and a manageable safety profile in the treatment of ICI-induced colitis and arthritis. Our findings support the feasibility of randomized trials of immune-related adverse events. Trial registration number NCT03601611.


  • Open Access

    Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

    by Julie Westerlin Kjeldsen, Cathrine Lund Lorentzen, Evelina Martinenaite, Eva Ellebaek, Marco Donia, Rikke Boedker Holmstroem, Tobias Wirenfeldt Klausen, Cecilie Oelvang Madsen, Shamaila Munir Ahmed, Stine Emilie Weis-Banke, et al.


  • Open Access

    A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

    by Julie Westerlin Kjeldsen, Cathrine Lund Lorentzen, Evelina Martinenaite, Eva Ellebaek, Marco Donia, Rikke Boedker Holmstroem, Tobias Wirenfeldt Klausen, Cecilie Oelvang Madsen, Shamaila Munir Ahmed, Stine Emilie Weis-Banke, et al.

    Anti-programmed death (PD)-1 (aPD1) therapy is an effective treatment for metastatic melanoma (MM); however, over 50% of patients progress due to resistance. We tested a first-in-class immune-modulatory vaccine (IO102/IO103) against indoleamine 2,3-dioxygenase (IDO) and PD ligand 1 (PD-L1), targeting immunosuppressive cells and tumor cells expressing IDO and/or PD-L1 (IDO/PD-L1), combined with nivolumab. Thirty aPD1 therapy-naive patients with MM were treated in a phase 1/2 study (https://clinicaltrials.gov/, NCT03047928). The primary endpoint was feasibility and safety; the systemic toxicity profile was comparable to that of nivolumab monotherapy. Secondary endpoints were efficacy and immunogenicity; an objective response rate (ORR) of 80% (confidence interval (CI), 62.7–90.5%) was reached, with 43% (CI, 27.4–60.8%) complete responses. After a median follow-up of 22.9 months, the median progression-free survival (PFS) was 26 months (CI, 15.4–69 months). Median overall survival (OS) was not reached. Vaccine-specific responses assessed in vitro were detected in the blood of >93% of patients during vaccination. Vaccine-reactive T cells comprised CD4+ and CD8+ T cells with activity against IDO- and PD-L1-expressing cancer and immune cells. T cell influx of peripherally expanded T cells into tumor sites was observed in responding patients, and general enrichment of IDO- and PD-L1-specific clones after treatment was documented. These clinical efficacy and favorable safety data support further validation in a larger randomized trial to confirm the clinical potential of this immunomodulating approach.


  • Open Access

    Clinical efficacy and immunity of a novel immune-modulatory peptide vaccine against IDO/PD-L1 (IO102/IO103) in combination with nivolumab in patients with metastatic melanoma

    by Julie Kjeldsen, Cathrine Lorentzen, Evelina Martinenaite, Eva Ellebaek, Marco Donia, Rikke Holmstroem, Tobias Klausen, Helle Hendel, Eva Ehrnrooth, Mai-Britt Zocca, et al.

    Anti-PD-1 (aPD1) therapy is an effective treatment for metastatic melanoma (MM); however, >50% of the patients progress due to resistance. Improved combination therapies enhancing aPD1 efficacy without leading to increased toxicity are needed. In this non-randomized phase I/II study (ClinicalTrials.gov: NCT03047928), we treated 30 aPD1 naive MM patients with a novel immune-modulatory vaccine (IO102/IO103) activating indoleamine 2,3-dioxygenase (IDO) and programmed death ligand-1 (PD-L1) specific T-cells combined with nivolumab. The vaccine has a dual mechanism of action, targeting both immunosuppressive cells and tumour cells expressing IDO/PD-L1. The vaccine was administered every two weeks for the first 6 injections and every fourth week thereafter, for up to 15 vaccines. Nivolumab was administered every two weeks (3mg/kg) for a maximum of 2 years. The primary endpoint was safety and feasibility; the systemic toxicity profile was comparable to nivolumab monotherapy, except for local and transient reactions at the vaccination site. Secondary endpoints were clinical efficacy and immunogenicity. An ORR of 80% (CI: 62.7-90.5%) was reached, with the majority of 43% (CI: 27.4-60.8%) achieving a complete response. After a median follow-up of 22.9 months, the median PFS was 26 months (CI: 15.4-69). Vaccine-specific responses were detected in vitro in blood from >93% of the patients on vaccination, suggesting the induction of memory response up to 6 months after the last vaccine. Vaccine reactive T-cells comprised both CD4+ and CD8+ T-cells. Paired biopsies from five patients with matched longitudinal PBMCs showed T-cell influx at the tumour site of peripherally expanded T-cells in responding patients and general enrichment of IDO and PD-L1 clones after treatment. These unprecedented clinical efficacy data support further validation in a larger randomized trial, to confirm the clinical potential of this first-in-class immunomodulating vaccine.